Intracavernosal Injection of Vasoactive Agents

Abstract

The National Institutes of Health consensus statement on impotence estimates that the number of men with erectile dysfunction in the United States is approx 20 million, presenting with varying degrees of erectile dysfunction. Although significant improvements in the pathophysiology have resulted in newer treatment modalities for the management of erectile dysfunction, intracavernosal vasoactive pharmacotherapy has been successfully utilized as a second-tier modality. These methods, the use of injection pharmacotherapy, account for approx 40% of all treatment options for the management of male sexual dysfunction. Tremendous progress in the use of monotherapy, and subsequent bimix, in conjunction with triple injection therapy, has resulted in improved modalities of treatment satisfaction.